MHRA authorises enzyme inhibitor Anastrozole to prevent breast cancer in post-menopausal women
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.